Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Company Limited, is located in Suzhou, Jiangsu Province.

愛美津制藥致力于仿制藥所涉及到全部階段的業(yè)務(wù)，是一家包括美國和中國多成員企業(yè)的集團(tuán)公司。集團(tuán)由愛美津制藥控股。美國市場的注冊和商業(yè)活動由位于新澤西州，林赫斯特，美國愛美津負(fù)責(zé)；集團(tuán)的中國分公司，蘇州愛美津制藥有限公司，位于中國江蘇省蘇州市。

The group has products on the market currently in both the US and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese CFDA.

愛美津制藥集團(tuán)目前在美國和中國均有藥品上市和銷售，同時我們擁有活躍的在研產(chǎn)品組，面向美國食品藥品監(jiān)督管理局（FDA）注冊和已申報若干個仿制藥品種（ANDA），并計劃開展向中國食品藥品監(jiān)督管理局（CFDA）注冊和申報產(chǎn)品的工作。

Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.

愛美津從事開發(fā)的口服制劑產(chǎn)品，是開發(fā)難度高，需要專門技術(shù)，或生產(chǎn)要求高度嚴(yán)格管理控制，以及法規(guī)復(fù)雜，需要規(guī)避或挑戰(zhàn)專利的仿制藥。愛美津集團(tuán)旗下公司或合作方開發(fā)和生產(chǎn)的所有產(chǎn)品，都滿足高質(zhì)量標(biāo)準(zhǔn)，包括美國FDA。